Panelists discuss how SGLT2 inhibitors evolved from diabetes medications to become foundational heart failure therapy with class I recommendations across the ejection fraction spectrum, providing ...
Camzyos is the first and only FDA-approved cardiac myosin inhibitor that specifically targets the source of obstructive HCM PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today ...
Dialysis may improve outcomes in patients suffering from treatment-resistant congestive heart failure (CHF) accompanied by severe renal insufficiency, new findings suggest. Trijntje T. Cnossen, MD, ...
Panelists discuss how β-blockers remain foundational therapy for heart failure with reduced ejection fraction (using evidence-based agents like carvedilol, metoprolol succinate, or bisoprolol) with ...
The researchers of a recent British Medical Journal paper reviewed heart failure diagnosis and management data. Heart failure has led to considerable health and financial burdens globally, especially ...
Adults who have heart failure with a left ventricular ejection fraction of 40% or more face a high risk of hospitalization for heart failure and cardiovascular death. People who have heart failure ...
Injectafer® approved in the U.S. for the treatment of iron deficiency in patients with heart failure
Injectafer® (ferric carboxymaltose) is now the first and only intravenous (i.v.) iron replacement therapy in the U.S. indicated for improvement in exercise capacity in adult patients with symptomatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results